Session » Genetics, Genomics & Proteomics Poster

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0898

A Blood Transcriptome Signature Distinguishes Between Diverse Systemic Autoimmune Diseases and Infection

10:30AM-12:30PM: Abstract Number: 0886

A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0911

Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

10:30AM-12:30PM: Abstract Number: 0915

APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism

10:30AM-12:30PM: Abstract Number: 0900

Association Between Serum Urate, Gout, and Prostatic Cancer in European Male Populations: A Mendelian Randomization Study

10:30AM-12:30PM: Abstract Number: 0907

Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol

10:30AM-12:30PM: Abstract Number: 0908

Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci

10:30AM-12:30PM: Abstract Number: 0904

Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing

10:30AM-12:30PM: Abstract Number: 0903

Distinct Impacts of Mosaic Loss of Chromosome Y and Genetic Risk on the Age of Onset in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0897

Dynamic eQTLs from Activated Human B Cells Suggest Cell-state Dependent Effects for GWAS Risk Variants in BLK

10:30AM-12:30PM: Abstract Number: 0884

Genetic Architecture Divergence in Sjögren’s Disease Subphenotypes and Populations: Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Cases in European Populations

10:30AM-12:30PM: Abstract Number: 0888

Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts

10:30AM-12:30PM: Abstract Number: 0905

High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes

10:30AM-12:30PM: Abstract Number: 0894

HOXD13 Regulation of Primary Cilia in Rheumatoid Arthritis Synovial Fibroblasts: Implications for Joint-Specific Pathogenesis

10:30AM-12:30PM: Abstract Number: 0896

Identification of Immune Pathways Regulated by a Non-Coding Variant at DNASE1L3/PXK/PDHB

10:30AM-12:30PM: Abstract Number: 0887

Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort

10:30AM-12:30PM: Abstract Number: 0909

Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

10:30AM-12:30PM: Abstract Number: 0901

Intergenic Alu Elements Are Uniquely Expressed in Dermatomyositis and Correlate with Interferon Stimulated Genes

10:30AM-12:30PM: Abstract Number: 0916

Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia

10:30AM-12:30PM: Abstract Number: 0912

Next-Generation Sequencing in Molecular Genetics of Adult-Onset Still’s Disease: Data from 23 Patients and Literature Review

10:30AM-12:30PM: Abstract Number: 0902

Novel Role of TYK2mechanism in SLE Pathogenesis via T Cell and B Cell Pathways

10:30AM-12:30PM: Abstract Number: 0892

Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR

10:30AM-12:30PM: Abstract Number: 0890

Pervasive Inflammation Poisons Hematopoiesis and Drives Clonal Dominance in VEXAS Syndrome

10:30AM-12:30PM: Abstract Number: 0895

Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis

10:30AM-12:30PM: Abstract Number: 0899

Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0906

Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers

10:30AM-12:30PM: Abstract Number: 0914

RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine

10:30AM-12:30PM: Abstract Number: 0910

Reduced Adenosine-Mediated Regulatory Activity Exacerbated by an NT5E Loss of Function Mutation Is Linked to Tissue Inflammation and Hypertension in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0885

Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions

10:30AM-12:30PM: Abstract Number: 0917

Role of Mutual Information Profile Shifts in Assessing the Pathogenicity of Mutations on Protein Functions: The Case of Pyrin Mutations in Familial Mediterranean Fever

10:30AM-12:30PM: Abstract Number: 0891

Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells

10:30AM-12:30PM: Abstract Number: 0913

The Association Between PTPN2 and Leukopenia in New Users of Azathioprine

10:30AM-12:30PM: Abstract Number: 0893

Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response

10:30AM-12:30PM: Abstract Number: 0889

Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].